120 related articles for article (PubMed ID: 22900295)
21. Biological significance of phosphorylation and myristoylation in the regulation of cardiac muscle proteins.
Raju RV; Kakkar R; Radhi JM; Sharma RK
Mol Cell Biochem; 1997 Nov; 176(1-2):135-43. PubMed ID: 9406155
[TBL] [Abstract][Full Text] [Related]
22. Ca(2+)/calmodulin-activated phosphodiesterase 1A is highly expressed in rabbit cardiac sinoatrial nodal cells and regulates pacemaker function.
Lukyanenko YO; Younes A; Lyashkov AE; Tarasov KV; Riordon DR; Lee J; Sirenko SG; Kobrinsky E; Ziman B; Tarasova YS; Juhaszova M; Sollott SJ; Graham DR; Lakatta EG
J Mol Cell Cardiol; 2016 Sep; 98():73-82. PubMed ID: 27363295
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of calmodulin alters its potency as an activator of target enzymes.
Quadroni M; L'Hostis EL; Corti C; Myagkikh I; Durussel I; Cox J; James P; Carafoli E
Biochemistry; 1998 May; 37(18):6523-32. PubMed ID: 9572870
[TBL] [Abstract][Full Text] [Related]
25. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue.
Gonçalves RL; Lugnier C; Keravis T; Lopes MJ; Fantini FA; Schmitt M; Cortes SF; Lemos VS
Eur J Pharmacol; 2009 Oct; 620(1-3):78-83. PubMed ID: 19686719
[TBL] [Abstract][Full Text] [Related]
26. Determination of Ca2+/calmodulin-stimulated phosphodiesterase activity in intact cells.
Yan C
Methods Mol Biol; 2005; 307():85-92. PubMed ID: 15988057
[TBL] [Abstract][Full Text] [Related]
27. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
Grewal J; Karuppiah N; Mutus B
Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
[TBL] [Abstract][Full Text] [Related]
28. Regulation of contractile activity in vascular smooth muscle by protein kinases.
Silver PJ
Rev Clin Basic Pharm; 1985; 5(3-4):341-95. PubMed ID: 3029813
[TBL] [Abstract][Full Text] [Related]
29. Sequence comparison of the 63-, 61-, and 59-kDa calmodulin-dependent cyclic nucleotide phosphodiesterases.
Novack JP; Charbonneau H; Bentley JK; Walsh KA; Beavo JA
Biochemistry; 1991 Aug; 30(32):7940-7. PubMed ID: 1651112
[TBL] [Abstract][Full Text] [Related]
30. Kinetic properties of Ca2+/calmodulin-dependent phosphodiesterase isoforms dictate intracellular cAMP dynamics in response to elevation of cytosolic Ca2+.
Goraya TA; Masada N; Ciruela A; Willoughby D; Clynes MA; Cooper DM
Cell Signal; 2008 Feb; 20(2):359-74. PubMed ID: 18335582
[TBL] [Abstract][Full Text] [Related]
31. [Ca
Kogiso H; Hosogi S; Ikeuchi Y; Tanaka S; Inui T; Marunaka Y; Nakahari T
Exp Physiol; 2018 Mar; 103(3):381-390. PubMed ID: 29282782
[TBL] [Abstract][Full Text] [Related]
32. Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases.
Sonnenburg WK; Seger D; Kwak KS; Huang J; Charbonneau H; Beavo JA
J Biol Chem; 1995 Dec; 270(52):30989-1000. PubMed ID: 8537356
[TBL] [Abstract][Full Text] [Related]
33. Enzymatic activity of the CaM-PDE1 system upon addition of actinyl ions.
Brulfert F; Safi S; Jeanson A; Foerstendorf H; Weiss S; Berthomieu C; Sauge-Merle S; Simoni É
J Inorg Biochem; 2017 Jul; 172():46-54. PubMed ID: 28427004
[TBL] [Abstract][Full Text] [Related]
34. Characterization of calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes.
Sharma RK; Kalra J
Biochem J; 1994 Apr; 299 ( Pt 1)(Pt 1):97-100. PubMed ID: 8166665
[TBL] [Abstract][Full Text] [Related]
35. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins.
Butt E; Beltman J; Becker DE; Jensen GS; Rybalkin SD; Jastorff B; Beavo JA
Mol Pharmacol; 1995 Feb; 47(2):340-7. PubMed ID: 7870042
[TBL] [Abstract][Full Text] [Related]
36. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.
Wennogle LP; Hoxie H; Peng Y; Hendrick JP
Adv Neurobiol; 2017; 17():349-384. PubMed ID: 28956339
[TBL] [Abstract][Full Text] [Related]
37. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
38. Calcium-dependent and -independent interactions of the calmodulin-binding domain of cyclic nucleotide phosphodiesterase with calmodulin.
Yuan T; Walsh MP; Sutherland C; Fabian H; Vogel HJ
Biochemistry; 1999 Feb; 38(5):1446-55. PubMed ID: 9931009
[TBL] [Abstract][Full Text] [Related]
39. Crustacean molt-inhibiting hormone: structure, function, and cellular mode of action.
Nakatsuji T; Lee CY; Watson RD
Comp Biochem Physiol A Mol Integr Physiol; 2009 Feb; 152(2):139-48. PubMed ID: 19000932
[TBL] [Abstract][Full Text] [Related]
40. TcrPDEA1, a cAMP-specific phosphodiesterase with atypical pharmacological properties from Trypanosoma cruzi.
Alonso GD; Schoijet AC; Torres HN; Flawiá MM
Mol Biochem Parasitol; 2007 Mar; 152(1):72-9. PubMed ID: 17222469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
